Previous close | 87.47 |
Open | 87.90 |
Bid | 86.27 x 1000 |
Ask | 92.34 x 900 |
Day's range | 87.90 - 87.95 |
52-week range | 82.86 - 206.36 |
Volume | |
Avg. volume | 40,828 |
Market cap | 474.199M |
Beta (5Y monthly) | 0.83 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.14 |
Earnings date | 05 Feb 2024 - 09 Feb 2024 |
Forward dividend & yield | 0.64 (0.73%) |
Ex-dividend date | 29 Nov 2023 |
1y target est | 115.00 |
LAKEWOOD, Colo., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q24”) ended September 30, 2023. Second quarter FY 2024 compared to second quarter FY 2023: Revenues decreased 9.5% but increased 5.0% vs 1Q24Non-GAAP core organic revenues3 decreased 10.1% but increased 2.7% vs. 1Q24Operating income decreased
Penumbra and Mesa Labs are part of the Zacks Bull and Bear of the Day article.
Mesa diagnostics gains importance among big pharma so we want to watch this dip